logo
Plus   Neg
Share
Email

Novartis Says MS Drug Gilenya Shows Long-term Efficacy, Safety In Extended Study

Swiss drugmaker Novartis AG (NVS) on Monday said a new data for multiple sclerosis drug Gilenya (fingolimod) showed long-term efficacy benefit and a consistent safety profile.

Gilenya, licensed from Japan's Mitsubishi Tanabe Pharma Corp., is the only oral therapy approved to treat people with relapsing forms of multiple sclerosis.

The data from single-arm extension of phase III head-to-head TRANSFORMS study showed sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment for up to 4.5 years, the company noted

The results also showed improved efficacy for patients switched to Gilenya from Avonex (interferon-beta-1a IM), a commonly prescribed MS treatment from Biogen Idec Inc. (BIIB). Novartis noted that reductions in relapses and MRI measures were observed in these patients.

In the core TRANSFORMS study, Gilenya demonstrated superior efficacy to Avonex, reducing the annualized relapse rate by 52% at one year. The extension study showed that this low relapse rate was sustained in patients receiving continuous treatment with Gilenya for up to 4.5 years.

As per the study results, patients treated with Gilenya continuously maintained a low brain atrophy rate throughout the study as measured by assessing brain volume loss, which is valued as a predictor of long-term disability, the company said.

The company also said that these extension data also showed that long-term treatment with Gilenya was generally well tolerated with a safety profile consistent with pivotal trials.

Tim Wright, Global Head of Development, Novartis Pharma, said, "These data further reinforce our confidence in Gilenya's long-term effectiveness and safety profile. The TRANSFORMS extension study shows that MS patients treated continuously with Gilenya for up to four and a half years demonstrated sustained low levels of clinical and MRI activity."

"The results, which are consistent with the pivotal phase III studies, confirm that fingolimod is highly effective in treating relapsing forms of MS, and as the first available oral MS treatment, continues to be a valuable treatment option for appropriate patients," the company noted in its statement.

These data were presented at the 22nd Annual Meeting of the European Neurological Society, taking place 9-12 June 2012 in Prague, Czech Republic.

In the U.S., Novartis shares closed Friday's regular trading session at $52.47, up $0.29 or 0.56 percent.

Mitsubishi Tanabe shares are currently trading at 1,060 yen, down 13 yen or 1.21 percent in Japan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year. Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow.
Follow RTT